TSV-2 Intranasal (IBR +PI3) 50-Dose Tank
Bovine Rhinotracheitis-Parainfluenza3 Vaccine, Modified Live Virus (IBR-PI3), cattle (including pregnant cows). Preservative: Gentamicin. Meat withdrawal: 21 days.
TSV-2�
Zoetis
Bovine Rhinotracheitis-Parainfluenza3 Vaccine, Modified Live Virus
U.S. Vet. Lic. No.: 190
Description: The vaccine is prepared by growing attenuated virus strains on a bovine cell line. The virus fractions are combined and stabilized by freeze-drying. A sterile diluent is supplied for rehydration.
Contains gentamicin as preservative.
Indications: TSV-2� is for vaccination of healthy cattle, including pregnant cows, as an aid in preventing infectious bovine rhinotracheitis caused by infectious bovine rhinotracheitis (IBR) virus and disease caused by parainfluenza3 (PI3) virus.
Directions:
1. General Directions: Vaccination of healthy cattle, including pregnant cows, is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, shake well, and administer 2 mL intranasally using a cannula or a syringe with the needle removed. Place half the dose (1 mL) in each nostril.
2. Primary Vaccination: Administer a single 2-mL dose to healthy cattle. Calves vaccinated before the age of 6 months should be revaccinated after 6 months of age to avoid possible maternal antibody interference with immunization.
3. Revaccination: Annual revaccination with a single dose is recommended.
4. Good animal husbandry and herd health management practices should be employed.
Precaution(s): Store at 2�-7�C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.
Use entire contents when first opened.
Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.
Warning(s): Do not vaccinate within 21 days before slaughter.
For veterinary use only.
Discussion: TSV-2� is unique in that the virus strains it contains are temperature-specific. Tests have shown that they will not grow in vivo at or above 39�C,1 the normal bovine body temperature. This restricts viral replication to the nasal mucosa, which is constantly ventilated and maintained at temperatures less than 39�C, even in the febrile animal. At this localized site, the temperature-specific viruses replicate and stimulate local and systemic immunity.2 Because the temperature-specific strains cannot grow in the internal body organs or developing fetus, pregnant cows may be safely vaccinated. Stimulation of a localized immune response also results in a rapid onset of protection.
